<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971152</url>
  </required_header>
  <id_info>
    <org_study_id>F-GYN-08-02</org_study_id>
    <nct_id>NCT00971152</nct_id>
  </id_info>
  <brief_title>Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle</brief_title>
  <official_title>Effect of a Higher Than Maximum 450IU Gonadotropin Dose on Patient Outcomes in an In-Vitro Fertilization Setting: a Randomized Controlled Non-infertility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OVO R &amp; D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OVO R &amp; D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where
      a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily
      dose is administered for women who are at risk of a poor ovarian response in order to
      determine if one dose or the other results in improved cycle outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of metaphase II oocytes retrieved during the course of one treatment cycle</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of follicles recruited per patient during stimulation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate per patient (number of normally fertilized (with 2 pronuclei) oocytes/number of mature oocytes collected)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo cleavage rate per patient (number of divided normally fertilized oocytes/number of normally fertilized oocytes)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos available per patient</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of supernumerary embryos available for cryopreservation per patient</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of multiple gestation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of occurrence of ovarian hyperstimulation syndrome (OHSS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>450 IU daily dose of gonadotrophin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>600 IU daily dose of gonadotrophin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>menotropins for injection</intervention_name>
    <description>comparison of different dosages</description>
    <arm_group_label>450 IU daily dose of gonadotrophin</arm_group_label>
    <arm_group_label>600 IU daily dose of gonadotrophin</arm_group_label>
    <other_name>Menopur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>urofollitropin for injection</intervention_name>
    <description>comparison of different dosages</description>
    <arm_group_label>450 IU daily dose of gonadotrophin</arm_group_label>
    <arm_group_label>600 IU daily dose of gonadotrophin</arm_group_label>
    <other_name>Bravelle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RESIDENT OF CANADA

          -  Premenopausal

          -  Age 40 years or less at the time of enrollment

          -  At risk of a poor ovarian response defined as: either &lt;5 oocytes or &lt;8 follicles in a
             previous cycle, FSH &gt; 10 IU/L, AMH &lt; 1 pg/ml , antral follicle count less or equal to
             8 or previous IVF cancellation

          -  Primary infertility or secondary

          -  Not previously undertaken a cycle that was included in this study

        Exclusion Criteria:

          -  Simultaneous participation in another clinical trial

          -  Body mass index (BMI) &gt; 38 kg/m2

          -  Early follicular phase (day 2-4) serum FSH level &gt; 20 mIU/ml

          -  Any contraindication to being pregnant and carrying a pregnancy to term

          -  Contraindication for the use of Estrace® , Suprefact®, Menopur®, Bravelle®, hCG, and
             luteal phase support medication

          -  Any ovarian or abdominal abnormality that may interfere with adequate transvaginal
             ultrasound evaluation

          -  Administration of any investigational drugs within three months prior to study
             enrollment

          -  Patient not able to communicate adequately with the investigators and to comply with
             the requirements of the entire study

          -  Positive results of screening of either partner for HIV antibodies, Hepatitis B (other
             than for surface antibodies present after vaccination) or Hepatitis C

          -  Unwillingness to give written informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Lapensee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OVO Fertilité</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Kadoch, MD</last_name>
    <role>Study Director</role>
    <affiliation>OVO Fertilité and OVO R &amp; D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ovo Fertilité</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ovoclinic.com/</url>
    <description>OVO fertilité website</description>
  </link>
  <reference>
    <citation>Srouji SS, Missmer SA, Ginsburg ES (2004) Impact of increasing gonadotropins &gt; 450 IU on cycle outcome. Brigham and Women's Hospital, Boston, MA. Fertil Steril 82 (Suppl 2): P292.</citation>
  </reference>
  <reference>
    <citation>Flisser E, Krey LC, Berkeley AS (2005) Diminishing Returns of Increasing Gonadotropin Dosage in Subsequent In Vitro Fertilization (IVF) Cycles?. Fertil Steril 84 (Suppl 1) P483.</citation>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>dose comparison of gonadotrophins</keyword>
  <keyword>poor responder to ovarian stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

